- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approves Eylea to Treat Diabetic Retinopathy in Patients With Diabetic Macular Edema
Diabetic retinopathy affects 33% of all patients with diabetes over 40; 29 million Americans have type 1 or type 2 diabetes.
The FDA today approved the use of Eylea (afilbercept) injections to treat diabetic retinopathy in patients who have diabetic macular edema (DR), the most common diabetic eye disease and a leading cause of blindness in adults.
According to CDC, this disease affects more than 33% of adults with diabetes age 40 and older had some form of DR; with 29 million Americans suffering either type 1 or type 2 diabetes, the potential for DR is significant in the US population.
Eylea, made by Regeneron, is administered through monthly injections for 5 months, then every 2 months. It is intended to be used alongside a modified diet and other interventions to control blood sugar, blood pressure, and cholesterol.
Safety and efficacy of Eylea to treat DR patients with DME evaluated in 2 clinical trials involving 679 patients. They were randomly assigned to have Eylea or macular laser photocoagulation, a laser treatment that burns small areas of the retina. At week 100, patients with Eylea showed significant improvement over those with the laser treatments.
Common side effects were bleeding of the conjunctiva, eye pain, cataracts, floaters, increased eye pressure, and separation of the interior jelly of the eye from the retina. Serious event included retinal detachments and infections within the eye.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
